Cargando…

Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls

OBJECTIVES: Human immune deficiency virus (HIV) is associated with increased cardiovascular disease (CVD) risk, yet the relationship between HIV and carotid atherosclerosis / monocyte activation among virally suppressed HIV-infected patients in sub-Saharan Africa is not well understood. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosepele, Mosepele, Hemphill, Linda C., Moloi, Walter, Moyo, Sikhulile, Nkele, Isaac, Makhema, Joseph, Bennett, Kara, Triant, Virginia A., Lockman, Shahin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491105/
https://www.ncbi.nlm.nih.gov/pubmed/28662159
http://dx.doi.org/10.1371/journal.pone.0179994
_version_ 1783247081238953984
author Mosepele, Mosepele
Hemphill, Linda C.
Moloi, Walter
Moyo, Sikhulile
Nkele, Isaac
Makhema, Joseph
Bennett, Kara
Triant, Virginia A.
Lockman, Shahin
author_facet Mosepele, Mosepele
Hemphill, Linda C.
Moloi, Walter
Moyo, Sikhulile
Nkele, Isaac
Makhema, Joseph
Bennett, Kara
Triant, Virginia A.
Lockman, Shahin
author_sort Mosepele, Mosepele
collection PubMed
description OBJECTIVES: Human immune deficiency virus (HIV) is associated with increased cardiovascular disease (CVD) risk, yet the relationship between HIV and carotid atherosclerosis / monocyte activation among virally suppressed HIV-infected patients in sub-Saharan Africa is not well understood. METHODS: We measured traditional CVD risk factors, bilateral distal common carotid intima media thickness (cIMT), presence of carotid plaque and plasma sCD163 levels among virally suppressed HIV-infected adults and HIV-uninfected controls, in a cross-sectional study in Gaborone, Botswana. The associations between HIV status, traditional CVD risk factors, sCD163 and outcome of cIMT were assessed in univariate and multivariate linear regression models. RESULTS: We enrolled 208 HIV-infected adults (55% Female, mean age 39 years) who had undetectable HIV-1 RNA on antiretroviral therapy and 224 HIV-uninfected controls (47% Female, mean age 37 years). There was no difference in cIMT between study groups, with mean cIMT 0.607mm and 0.599mm in HIV-infected and HIV-uninfected, respectively (p = 0.37). Plasma sCD163 was significantly higher in HIV-infected versus HIV-uninfected persons (1917ng/ml vs 1593ng/ml, p = 0.003), but was not associated with cIMT (p = 0.43 among all, p = 0.72 for HIV-infected only). In the final multivariate model, increased cIMT was associated with older age, being treated for hypertension, and higher non-HDL cholesterol among all (p<0.001, p = 0.03, p<0.001 respectively), and with older age and waist-hip ratio in HIV-infected participants (p = 0.02 & p = 0.02 respectively). Carotid plaque was present in a significantly higher proportion of HIV-infected adults (RR 2.15, 95% CI 1.22, 3.81). CONCLUSIONS: HIV-infected participants aged 30–50 years who have achieved viral suppression did not have increased cIMT when compared to HIV-uninfected controls in Botswana. However, well-controlled HIV was associated with excess monocyte activation. Future work should explore the impact of subclinical atherosclerosis on CVD events among HIV-infected and -uninfected adults in Botswana.
format Online
Article
Text
id pubmed-5491105
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54911052017-07-18 Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls Mosepele, Mosepele Hemphill, Linda C. Moloi, Walter Moyo, Sikhulile Nkele, Isaac Makhema, Joseph Bennett, Kara Triant, Virginia A. Lockman, Shahin PLoS One Research Article OBJECTIVES: Human immune deficiency virus (HIV) is associated with increased cardiovascular disease (CVD) risk, yet the relationship between HIV and carotid atherosclerosis / monocyte activation among virally suppressed HIV-infected patients in sub-Saharan Africa is not well understood. METHODS: We measured traditional CVD risk factors, bilateral distal common carotid intima media thickness (cIMT), presence of carotid plaque and plasma sCD163 levels among virally suppressed HIV-infected adults and HIV-uninfected controls, in a cross-sectional study in Gaborone, Botswana. The associations between HIV status, traditional CVD risk factors, sCD163 and outcome of cIMT were assessed in univariate and multivariate linear regression models. RESULTS: We enrolled 208 HIV-infected adults (55% Female, mean age 39 years) who had undetectable HIV-1 RNA on antiretroviral therapy and 224 HIV-uninfected controls (47% Female, mean age 37 years). There was no difference in cIMT between study groups, with mean cIMT 0.607mm and 0.599mm in HIV-infected and HIV-uninfected, respectively (p = 0.37). Plasma sCD163 was significantly higher in HIV-infected versus HIV-uninfected persons (1917ng/ml vs 1593ng/ml, p = 0.003), but was not associated with cIMT (p = 0.43 among all, p = 0.72 for HIV-infected only). In the final multivariate model, increased cIMT was associated with older age, being treated for hypertension, and higher non-HDL cholesterol among all (p<0.001, p = 0.03, p<0.001 respectively), and with older age and waist-hip ratio in HIV-infected participants (p = 0.02 & p = 0.02 respectively). Carotid plaque was present in a significantly higher proportion of HIV-infected adults (RR 2.15, 95% CI 1.22, 3.81). CONCLUSIONS: HIV-infected participants aged 30–50 years who have achieved viral suppression did not have increased cIMT when compared to HIV-uninfected controls in Botswana. However, well-controlled HIV was associated with excess monocyte activation. Future work should explore the impact of subclinical atherosclerosis on CVD events among HIV-infected and -uninfected adults in Botswana. Public Library of Science 2017-06-29 /pmc/articles/PMC5491105/ /pubmed/28662159 http://dx.doi.org/10.1371/journal.pone.0179994 Text en © 2017 Mosepele et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mosepele, Mosepele
Hemphill, Linda C.
Moloi, Walter
Moyo, Sikhulile
Nkele, Isaac
Makhema, Joseph
Bennett, Kara
Triant, Virginia A.
Lockman, Shahin
Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls
title Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls
title_full Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls
title_fullStr Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls
title_full_unstemmed Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls
title_short Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls
title_sort pre-clinical carotid atherosclerosis and scd163 among virally suppressed hiv patients in botswana compared with uninfected controls
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491105/
https://www.ncbi.nlm.nih.gov/pubmed/28662159
http://dx.doi.org/10.1371/journal.pone.0179994
work_keys_str_mv AT mosepelemosepele preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT hemphilllindac preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT moloiwalter preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT moyosikhulile preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT nkeleisaac preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT makhemajoseph preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT bennettkara preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT triantvirginiaa preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols
AT lockmanshahin preclinicalcarotidatherosclerosisandscd163amongvirallysuppressedhivpatientsinbotswanacomparedwithuninfectedcontrols